Market Overview

AbbVie's Phase IIb Aviator Trial Demonstrates High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1


Results from "Aviator,"  AbbVie's (NYSE: ABBV) phase IIb clinical trial of its investigational direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection, continue to demonstrate high sustained viral response (SVR) rates against genotype 1 HCV, across patient types. Data show greater than 90 percent SVR were achieved in patients new to treatment and in patients who had previously failed treatment with pegylated interferon and ribavirin (null responders). In addition, similar high SVR rates observed after 12 and 24 weeks of treatment in the Phase IIb trial reinforce the adequacy of the 12-week treatment duration for the investigational interferon-free, triple DAA combination.  The triple-DAA combination is currently being studied in Phase III clinical trials. Results will be featured in the official press conference at the 2013 International Liver Congress┬« (ILC) in Amsterdam on Wednesday, April 24 at 11:00 CEST and presented on Thursday, April 25.

"These new results from the Aviator

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (ABBV)

View Comments and Join the Discussion!